1421923-86-5

Basic information

• Product Name: KPT-330, (E)-RN
• Synonyms: KPT-330, (E)-RN;KPT-330, (E)-RN (E)-3-(3-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-1H-1,2,4-TRIAZOL-1-YL)-N'-(PYRAZIN-2-YL)ACRYLOHYDRAZIDE;(E)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide
• CAS NO: 1421923-86-5
• Molecular Formula: C₁₇H₁₁F₆N₇O
• Molecular Weight: 443.3059592
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 1421923-86-5.mol

Chemical Properties

• Appearance: /
• Density: 1.55±0.1 g/cm3(Predicted)
• PKA: 9.74±0.43(Predicted)
• CAS DataBase Reference: KPT-330, (E)-RN(CAS DataBase Reference)
• NIST Chemistry Reference: KPT-330, (E)-RN(1421923-86-5)
• EPA Substance Registry System: KPT-330, (E)-RN(1421923-86-5)

Safety Data

• Hazardous Substances Data: 1421923-86-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
KPT-330, (E)-RN is used as an anticancer agent for its ability to block pancreatic cancer cell proliferation and reduce tumor growth in mice. Its selective inhibition of CRM1 makes it a potential candidate for the development of targeted cancer therapies.
Used in Cancer Research:
KPT-330, (E)-RN is used as a research tool for studying the role of CRM1 in cancer cell proliferation and tumor growth. Its selective inhibition of CRM1 can provide valuable insights into the molecular mechanisms underlying cancer development and progression, potentially leading to the discovery of novel therapeutic targets and strategies.

Upstream product

• 317319-15-6 3,5-bis(trifluoromethyl)benzothioamide 
• 27126-93-8 3,5-bis(trifluoromethyl)benzonitrile 
• 1421923-95-6 (E)-isopropyl 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 
• 1421923-96-7 (E)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid 
• 54608-52-5 2-hydrazinylpyrazine 
• 1333154-10-1 3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazole 

Relevant articles and documents

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.